肾移植后初始他克莫司剂量按CYP3A5基因型调整的临床影响:随机对照试验的系统评价与Meta分析
该系统评价与Meta分析检索PubMed、EMBASE和Cochrane数据库至2020年2月26日,比较基因型指导与传统他克莫司剂量在肾移植患者中的临床结局。基因型指导组稳态时他克莫司浓度处于治疗范围的患者比例更高(RR 1.40,95%CI 1.14-1.72,p=0.001),但延迟移植肾功能恢复、急性排斥、移植物存活及不良反应发生率两组相似。作者认为基于CYP3A5基因型的药物基因组学指导他克莫司用药价值有限。
要点
- 基因型指导组稳态他克莫司浓度达标比例更高(RR 1.40)。
- 延迟移植肾功能恢复、急性排斥、移植物存活及不良反应两组无统计学差异。
- 作者结论:基于CYP3A5基因型指导他克莫司用药价值有限。
核心结论
- 基因型指导组他克莫司稳态浓度达标比例更高且达标时间有更早趋势,但延迟移植肾功能恢复、急性排斥、移植物存活(删失死亡)及不良反应等临床终点两组相似。
- 证据提示基于CYP3A5基因型的药物基因组学指导他克莫司用药无实用价值。
- 因CYP3A5基因多态性频率差异,仍需在中國及非裔美国人人群中开展研究。
- 建议考虑纳入人口学与临床因素及多个遗传变异制订给药算法,以优化他克莫司早期暴露。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、EMBASE和Cochrane数据库自建库至2020年2月26日。
- 检索词包括tacrolimus、cytochrome P-450 CYP3A、polymorphism,genetic、genomics、genome、genotype、genes、alleles和pharmacogenetics。
- 纳入比较基因型指导与传统他克莫司剂量在肾移植患者中临床结局的随机对照试验。
主要发现
- 基因型指导组稳态时他克莫司浓度处于治疗范围的患者比例更高(RR 1.40,95%CI 1.14-1.72,p=0.001;高质量)。
- 与传统组相比,基因型指导组达到治疗浓度有更早趋势。
- 延迟移植肾功能恢复发生率两组无统计学差异(RR 1.98,95%CI 0.92-1.76,p=0.12;中等质量)。
- 急性排斥发生率两组无统计学差异(RR 1.00,95%CI 0.64-1.55,p=1.00;中等质量)。
- 移植物存活(删失死亡)发生率两组无统计学差异(RR 1.02,95%CI 0.98-1.06,p=0.37;中等质量),不良反应发生率亦无差异。
关键数值与推荐
- 稳态他克莫司浓度处于治疗范围的患者比例:RR 1.40,95%CI 1.14-1.72,p=0.001,高质量证据。
- 延迟移植肾功能恢复:RR 1.98,95%CI 0.92-1.76,p=0.12,中等质量证据。
- 急性排斥:RR 1.00,95%CI 0.64-1.55,p=1.00,中等质量证据。
- 移植物存活(删失死亡):RR 1.02,95%CI 0.98-1.06,p=0.37,中等质量证据。
临床怎么用
- 肾移植患者初始他克莫司剂量按CYP3A5基因型调整可提高稳态浓度达标比例。
- 但现有证据未显示该策略改善延迟移植肾功能恢复、急性排斥、移植物存活或不良反应等临床终点。
- 基于CYP3A5基因型指导他克莫司用药的临床实用性有限,决策时需结合人群遗传多态性频率综合考虑。
局限性
- 研究指出仍需在中国及非裔美国人等CYP3A5基因多态性频率不同的人群中开展研究。
- 作者建议未来给药算法应纳入人口学与临床因素及多个遗传变异,提示现有基因型指导策略可能不够全面。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this systematic review and meta-analysis was to compare the clinical outcomes between genotype-guided and conventional tacrolimus doses in kidney transplantation patients. MATERIALS AND METHODS: We performed a comprehensive literature search of the PubMed, EMBASE, and Cochrane databases from the date of inception to 26 February 2020. References of the retrieved articles were also reviewed and any further relevant studies were included. The search terms included 'tacrolimus', 'cytochrome P-450 CYP3A', 'polymorphism, genetic', 'genomics', 'genome', 'genotype', 'genes', 'alleles', and 'pharmacogenetics'. RESULTS: Our study showed that the genotype-guided group included an increased proportion of patients with tacrolimus concentrations in the therapeutic range at steady state (risk ratio [RR] 1.40, 95% confidence interval [CI] 1.14-1.72, p = 0.001; high quality), with a trend for achieving therapeutic concentrations earlier compared with those in the conventional group. However, there was no statistical difference in the incidence of delayed graft function (RR 1.98, 95% CI 0.92-1.76, p = 0.12; moderate quality), incidence of acute rejection (RR 1.00, 95% CI 0.64-1.55, p = 1.00; moderate quality), incidence of graft survival censored for death (RR 1.02, 95% CI 0.98-1.06, p = 0.37; moderate quality), and incidence of adverse effects (AEs). CONCLUSIONS: Although the genotype-guided group had a higher proportion of patients within the targeted concentration and less median time to achieve the therapeutic range, the clinical endpoints, including delayed graft function, acute rejection, graft survival censored for death, and AEs were similar in both groups. All in all, evidence suggested there was no utility in pharmacogenetics for tacrolimus based on the cytochrome P450 (CYP) 3A5 genotype. Studies with Chinese and African American populations are needed due to the frequency of genetic polymorphisms of CYP3A5. Furthermore, a dosing algorithm that includes demographic and clinical factors plus multiple genetic variants should be added for consideration, and may optimize early tacrolimus exposure.
引用
- Yang H, Sun Y, Yu X, et al. Clinical Impact of the Adaptation of Initial Tacrolimus Dosing to the CYP3A5 Genotype After Kidney Transplantation: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clin Pharmacokinet. 2021. PMID: 33751414. doi:10.1007/s40262-020-00955-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。